Home / Technology
Core technological pillarsAt the core of PlasmaDtect lies a methodology that integrates ultra-sensitive biochemical assays with advanced computational engineering — delivering an exceptionally specific cancer readout within just four days.
A proprietary workflow that turns 10 ml of blood into an actionable, high-fidelity readout in four days.
Rapid isolation of low-abundance cell-free DNA, preserving fragile fragments without bisulfite damage.
Epigenetic methylation analysis runs in parallel with targeted proteomic signatures for maximum confidence.
A proprietary analytical pipeline optimized for the molecular epidemiology and epigenetic signatures of the Indian subcontinent.
Machine-learning interpretation filters biological noise to deliver high-fidelity MRD classification.
Each layer of our ecosystem is engineered to maximize sensitivity, specificity, and clinical relevance.
Traditional epigenetic analysis relies on chemical bisulfite conversion, which degrades up to 90% of retrieved genomic material. We use a sophisticated, non-destructive enzymatic conversion kit that preserves low-yield cfDNA fragments — ensuring maximum sensitivity even in early-stage or low-volume residual disease.
We merge distinct biological layers into a single assessment. Epigenetic profiling captures hypermethylated CpG islands across tumor signatures, while parallel proteomic signatures establish a secondary, phenotypic verification layer to maximize clinical specificity.
Global assays are historically derived from Western cohorts, leading to sub-optimal performance across distinct genetic backgrounds. Our pipeline is meticulously optimized for the molecular epidemiology and unique epigenetic variations of the Indian subcontinent — delivering unparalleled regional precision.
Interpreting multiplexed epigenetic and proteomic data requires advanced computational intelligence. Our proprietary machine-learning models, trained on cloud architecture, filter background biological noise and recognize complex multi-marker signature patterns — delivering automated, high-fidelity MRD classification.
cfDNA circulates at vanishingly low concentrations — especially in early-stage disease. Harsh chemical bisulfite conversion can destroy the very material we need to read.
Our non-destructive enzymatic approach keeps those low-yield fragments intact, so the signal survives all the way to the AI readout. That is the difference between catching disease early and missing it entirely.
The science of methylationOur scientific team is happy to walk clinical and research partners through assay design, validation data, and integration.
Talk to our scientists